ArticleScientific reports2025
Comprehensive analysis of coagulation-associated gene signature in bladder cancer diagnosis, prognosis, and immunotherapy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
In recent years, research on the relationship between coagulation system abnormalities and tumor immunity has been widely reported. Bladder cancer (BC), as an immunogenic tumor, holds great promise in immunotherapy. The role of coagulation-related genes in predicting the prognosis of BC patients and the efficacy of immunotherapy remains to be explored. In this study, we utilized the TCGA data system to analyze the biological functions of coagulation-related genes (CRGs) in BC patients. Additionally, we employed multiple machine learning methods (LASSO regression, SVM-RFE regression, and random forest) to establish diagnostic and prognostic signatures for BC based on CRGs. Univariate and multivariate Cox analyses indicated that the prognostic signature is an independent risk factor. Combining risk scores and independent clinical parameters, we established a Nomogram with a C-index of 0.812. Furthermore, we applied CRGs to cluster BC patients, and significant differences were observed between the two clusters in terms of immune cell infiltration, immune cell pathway activity, and response to immunotherapy. In conclusion, we systematically analyzed the value of CRGs in the diagnosis, prognosis, and personalized treatment of BC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.